GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » 5-Year Yield-on-Cost %

New Ray Medicine International Holding (HKSE:06108) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding 5-Year Yield-on-Cost %?

New Ray Medicine International Holding's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for New Ray Medicine International Holding's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 12 years, New Ray Medicine International Holding's highest Yield on Cost was 12.34. The lowest was 0.00. And the median was 5.14.


HKSE:06108's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.54
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of New Ray Medicine International Holding's 5-Year Yield-on-Cost %

For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


New Ray Medicine International Holding's 5-Year Yield-on-Cost % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where New Ray Medicine International Holding's 5-Year Yield-on-Cost % falls into.



New Ray Medicine International Holding 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of New Ray Medicine International Holding is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

New Ray Medicine International Holding  (HKSE:06108) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


New Ray Medicine International Holding 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines